World's Best Scientists 2026 revealed!
Satoshi Morita

Satoshi Morita

D-Index & Metrics

Medicine

D-Index
93
Citations
45308
World Ranking
10679
National Ranking
303

Overview

Satoshi Morita is a researcher affiliated with Kyoto University in Japan specializing in medicine, with a significant focus on oncology. Their scholarly work encompasses various subfields including oncology, pulmonary and respiratory medicine, cancer research, surgery, and molecular biology.

The main topics covered in their research include:

  • Lung Cancer Treatments and Mutations
  • Colorectal Cancer Treatments and Studies
  • Cancer Treatment and Pharmacology
  • HER2/EGFR in Cancer Research
  • Breast Cancer Treatment Studies
  • Gastric Cancer Management and Outcomes
  • Advanced Breast Cancer Therapies

Satoshi Morita has contributed to a number of research articles published in prominent journals. Some recent representative publications include:

  • Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, 2021, JAMA Oncology
  • International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO-GC-1), 2021, Annals of Gastroenterological Surgery
  • Validation Study of the International Association for the Study of Lung Cancer Histologic Grading System of Invasive Lung Adenocarcinoma, 2021, Journal of Thoracic Oncology
  • Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC, 2021, Journal of Thoracic Oncology
  • Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR, 2022, Journal of Clinical Oncology

The frequent co-authors collaborating with Morita are:

  • Masakazu Toi
  • Norikazu Masuda
  • Shinji Ohno
  • Kunihiko Kobayashi
  • Toshimi Takano

The primary journals where Morita's work is published consist of:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • International Journal of Clinical Oncology
  • Cancer Research
  • Journal of Thoracic Oncology

This profile reflects an active research trajectory centered on critical aspects of cancer treatment and molecular oncology, particularly in lung and gastric cancers, as well as targeted therapies related to EGFR mutations. The scientist maintains a broad collaboration network and regularly publishes in high-impact clinical oncology journals.

Best Publications

  • Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

    Makoto Maemondo;Akira Inoue;Kunihiko Kobayashi;Shunichi Sugawara

  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

    Tetsuya Mitsudomi;Satoshi Morita;Yasushi Yatabe;Shunichi Negoro

  • Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

    Junzo Hamanishi;Masaki Mandai;Takafumi Ikeda;Manabu Minami

  • Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model

    Tetsuhiro Kikuchi;Asuka Morizane;Daisuke Doi;Hiroaki Magotani

  • First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy

    Akira Inoue;Kunihiko Kobayashi;Kazuhiro Usui;Makoto Maemondo

  • Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

    A. Inoue;K. Kobayashi;M. Maemondo;S. Sugawara

  • Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

    Haruhiro Saito;Tatsuro Fukuhara;Naoki Furuya;Kana Watanabe

  • Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

    Shuichi Hironaka;Shinya Ueda;Hirofumi Yasui;Tomohiro Nishina

  • Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.

    Yukio Hosomi;Satoshi Morita;Shunichi Sugawara;Terufumi Kato

  • Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization.

    Manabu Morimoto;Kazushi Numata;Masaaki Kondou;Akito Nozaki

  • Sentinel Node Mapping for Gastric Cancer: A Prospective Multicenter Trial in Japan

    Yuko Kitagawa;Hiroya Takeuchi;Yu Takagi;Shoji Natsugoe

  • Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

    Jun Imagawa;Hideo Tanaka;Masaya Okada;Hirohisa Nakamae

  • Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease.

    S. Miyatake;N. Miyake;H. Touho;A. Nishimura-Tadaki

  • Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.

    Yasuhide Yamada;Daisuke Takahari;Hiroshi Matsumoto;Hideo Baba

  • Determining the effective sample size of a parametric prior

    Satoshi Morita;Peter F. Thall;Peter Müller

  • Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)

    Kei Muro;Narikazu Boku;Yasuhiro Shimada;Akihito Tsuji

  • Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.

    Shuichi Izumoto;Akihiro Tsuboi;Yoshihiro Oka;Tsuyoshi Suzuki

  • Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations

    Satoshi Morita;Isamu Okamoto;Kunihiko Kobayashi;Koichi Yamazaki

  • Frequency of and variables associated with the EGFR mutation and its subtypes

    Tomoaki Tanaka;Masaru Matsuoka;Akihisa Sutani;Akihiko Gemma

  • Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

    Kentaro Yamazaki;M. Nagase;H. Tamagawa;S. Ueda

Frequent Co-Authors

Masakazu Toi
Masakazu Toi Kyoto University
Yasuhiro Kodera
Yasuhiro Kodera Nagoya University
Kazuhiko Nakagawa
Kazuhiko Nakagawa Kindai University
Isamu Okamoto
Isamu Okamoto Kyushu University
Narikazu Boku
Narikazu Boku St. Marianna University School of Medicine
Yasuo Ohashi
Yasuo Ohashi Chuo University
Itaru Endo
Itaru Endo Yokohama City University
Toshihiro Nukiwa
Toshihiro Nukiwa Tohoku University
Kei Muro
Kei Muro National Cancer Research Institute, UK
Hideo Baba
Hideo Baba Kumamoto University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring healthcare careers isn’t limited to traditional, campus-based medical programs. Many students are finding flexibility and affordability through online degrees that lead to rewarding positions in the medical field. For registered nurses looking to advance, consider some of the cheapest accredited online rn to bsn programs to earn your bachelor’s degree without heavy financial pressure.

If you’re interested in the nurse practitioner route but don’t already have a nursing background, direct entry np programs for non nurses online offer a faster way to transition into advanced nursing roles.

Those starting out in nursing can check out online adn programs, which generally have lower barriers to entry and prepare students for RN licensure efficiently.

Interested in the administrative side of healthcare? Choose from the best online medical billing and coding schools to start a flexible, in-demand career supporting medical practices and health systems.

Best Scientists Citing Satoshi Morita

Trending Scientists

Recently Published Articles